High-dose medroxyprogesterone acetate versus prednisolone in hormone-resistant prostatic cancer. A pilot study.
Medroxyprogesterone acetate (MPA) (1,000 mg daily per os) yielded (mainly subjective) remissions in 8 of 21 patients with hormone-resistant cancer of the prostate. In 24 comparable patients, treated with prednisolone (20 mg daily per os) 3 remissions were observed, indicating a slight superiority of high-dose MPA considering the response rate. The response duration for both drugs was relatively short (2-7 months). No survival benefit for either drug was observed. In patients with hormone-resistant cancer of the prostate, a significant improvement of the performance status should be registrated as subjective response. This is a major aim of any treatment in these patients. Normalization of serum acid phosphatase may also be considered as remission. The type of remission (greater than 50% reduction of measurable tumor lesions, reduction of serum acid phosphatase, subjective remission) should always be indicated in the individual report dealing with phase II/phase III studies in patients with hormone-resistant prostatic cancer.
Fosså
S D
SD
Jahnsen
J U
JU
Karlsen
S
S
Ogreid
P
P
Haveland
H
H
Trovåg
A
A
D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D010865:Pilot Projects; D011239:Prednisolone / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011897:Random Allocation; D013997:Time Factors
D000970:Antineoplastic Agents; D011239:Prednisolone; D017258:Medroxyprogesterone Acetate; D000135:Acid Phosphatase; D008525:Medroxyprogesterone